Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience.
Andrea MarinoGabriella ZafaranaManuela CeccarelliFederica CosentinoVittoria MoscattGabriele BrunoRoberto BrunoFrancesco BenantiBruno CacopardoBenedetto Maurizio CelesiaPublished in: Diagnostics (Basel, Switzerland) (2021)
HCV treatment became available for all infected patients regardless of their comorbidities, especially for HIV coinfected subjects, leading to an improvement in both clinical and immunological conditions. We retrospectively analyzed a cohort of HIV/HCV coinfected patients treated with DAA therapies; data regarding epidemiological, viral-immunological, and hepatic parameters before and after DAA administration have been collected. Drug-drug interactions between DAA and both antiretroviral therapy and non-ART-drugs were also evaluated; the study showed the efficacy of DAA schedules in HCV eradication also for HIV/HCV patients with multiple comorbidities and assuming many different drugs. Principal issues are still represented by drug interactions, pill burden, and patients' compliance. These concerns have to be taken into account, especially in HIV patients for whom the immunological state and ART interactions should always be considered.
Keyphrases
- antiretroviral therapy
- hepatitis c virus
- human immunodeficiency virus
- hiv infected
- hiv positive
- end stage renal disease
- hiv aids
- hiv infected patients
- newly diagnosed
- hiv testing
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- emergency department
- risk factors
- patient reported outcomes
- south africa
- helicobacter pylori
- helicobacter pylori infection
- deep learning